Gocatamig Clinical Trials (2026): 3 Studies for Neuroendocrine Carcinoma & Small-Cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 Gocatamig clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Neuroendocrine Carcinoma & Small-Cell Lung Cancer) and 664 total planned enrollment. 2 Gocatamig clinical trials are actively recruiting at 21 U.S. sites across 15 states. Most recent activity: NCT07227597 (Dec 2030).
Where to Participate: All Gocatamig Trial Sites in the U.S. (21 sites across 15 states)
Every actively recruiting Gocatamigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Providence Medical Foundation ( Site 0124) | Santa Rosa95403 | NCT07227597 | Map |
| CO | University of Colorado Anschutz Medical Campus ( Site 1110) | Aurora80045 | NCT06780137 | Map |
| FL | University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111) | Miami33136 | NCT06780137 | Map |
| FL | Orlando Health Cancer Institute ( Site 0108) | Orlando32806 | NCT07227597 | Map |
| IL | University of Chicago ( Site 1108) | Chicago60637 | NCT06780137 | Map |
| KY | Saint Elizabeth Medical Center Edgewood ( Site 0112) | Edgewood41017 | NCT07227597 | Map |
| MA | Dana Farber Cancer Institute ( Site 1105) | Boston02215 | NCT06780137 | Map |
| MO | Washington University School of Medicine ( Site 0134) | St Louis63110 | NCT07227597 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101) | Hackensack07601 | NCT07227597 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103) | Hackensack07601 | NCT06780137 | Map |
| NY | Roswell Park Cancer Institute ( Site 1107) | Buffalo14263 | NCT06780137 | Map |
| OR | Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107) | Portland97213 | NCT07227597 | Map |
| OR | Providence Portland Medical Center ( Site 1101) | Portland97213 | NCT06780137 | Map |
| SD | Avera Cancer Institute- Research ( Site 0104) | Sioux Falls57105 | NCT07227597 | Map |
| TN | The University of Tennessee Medical Center ( Site 0120) | Knoxville37920 | NCT07227597 | Map |
| TN | Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133) | Memphis38105 | NCT07227597 | Map |
| TN | Sarah Cannon Research Institute ( Site 7001) | Nashville37203 | NCT06780137 | Map |
| TN | SCRI Oncology Partners ( Site 7000) | Nashville37203 | NCT07227597 | Map |
| TX | Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113) | Houston77030 | NCT07227597 | Map |
| VA | University of Virginia Health System ( Site 0122) | Charlottesville22908 | NCT07227597 | Map |
| WI | Medical College of Wisconsin ( Site 1112) | Milwaukee53226 | NCT06780137 | Map |
Gocatamig clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1/P2 | 2 | 1 | 3 |
Recruiting Gocatamig clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07227597 | MK-6070A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | P1/P2 | Small Cell Lung Cancer Extensive Stage | 170 | Jan 2026 |
| NCT06780137 | MK-6070A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | P1/P2 | Small Cell Lung Cancer | 262 | Feb 2025 |
Gocatamig clinical trials by indication
Small Cell Lung Cancer Extensive Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07227597 | MK-6070 | P1/P2 | recruiting | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) |
Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06780137 | MK-6070 | P1/P2 | recruiting | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) |
Small-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04471727 | — | P1/P2 | active not recruiting | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) |
All Gocatamig trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07227597 | MK-6070 | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | P1/P2 | recruiting | 170 | Merck Sharp & Dohme LLC | Jan 2026 |
| NCT06780137 | MK-6070 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | P1/P2 | recruiting | 262 | Merck Sharp & Dohme LLC | Feb 2025 |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | P1/P2 | active not recruiting | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Dec 2020 |
Gocatamig clinical trials: frequently asked questions
- How many Gocatamig clinical trials are there?
- 3 Gocatamig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are Gocatamig clinical trials recruiting in 2026?
- Yes — 2 Gocatamig trials are actively recruiting in 2026, with 21 U.S. sites across 15 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Gocatamig being studied for?
- Gocatamig is being studied for Neuroendocrine Carcinoma, Small-Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage. The trials are grouped by indication on this page.
- Who sponsors Gocatamig clinical trials?
- The lead sponsor across the most Gocatamig trials is Merck Sharp & Dohme LLC, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Gocatamigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: